- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
The Top 5 Biosimilars Articles for the Week of February 11
The Center for Biosimilars® recaps the top news for the week of February 11, 2019.
Transcript:
Hi, I’m Samantha DiGrande for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of February 11.
Number 5: Samsung Bioepis has announced a new licensing agreement with the private equity firm C-Bridge Capital that will allow the drug maker to expand its reach into China.
Number 4: A recent Australian study found that infliximab reduces short-term costs versus colectomy in patients with acute severe ulcerative colitis, and biosimilars could drive costs down even more.
Number 3: A recent study examining Medicare Part D reimbursement policies for off-label uses found that coverage decisions could hamper patient access.
Number 2: In a long-running patent dispute, AbbVie has been ordered to produce documents related to its efforts to obtain patents to shield Humira from biosimilar competition.
Number 1: During a presentation at the Access! 2019 meeting, an IQVIA executive broke down market share data for US biosimilars.
Finally, last week, our e-newsletter asked whether you think that all biosimilars, not just interchangeable ones, should be substitutable at the pharmacy level.
To view results of the poll, visit us on LinkedIn.
To read all of these articles and more, visit centerforbiosimilars.com.
The Banking of Biosimilars: Insights From a Leading Health Economist
February 4th 2025Biosimilars have the potential to reduce health care costs and expand patient access, but economic and policy barriers affect adoption, explored James D. Chambers, PhD, MPharm, MSc, associate professor at the Tufts Medical Center Institute for Clinical Research and Health Policy Studies, in an interview.
Biosimilars Policy Roundup for September 2024—Podcast Edition
October 6th 2024On this episode of Not So Different, we discuss the FDA's approval of a new biosimilar for treating retinal conditions, which took place in September 2024 alongside other major industry developments, including ongoing legal disputes and broader trends in market dynamics and regulatory challenges.
A Banner Year for Biosimilars: The 19 FDA Approvals From 2024
January 21st 2025In 2024, the FDA approved 19 biosimilars across various therapeutic areas, including the first biosimilars for ustekinumab and denosumab, marking significant progress in expanding treatment options and market competition.
FTC Releases Second Report on PBMs Meddling in Generic Drug Markets
January 19th 2025The 3 largest pharmacy benefit managers (PBMs) increased many specialty generic drugs prices by hundreds of percent, with some drugs seeing thousands of percent markups, according to the Federal Trade Commission (FTC)’s second interim report on PBM practices.
